158 related articles for article (PubMed ID: 38818367)
1. Achieving long-term survival in extensive-stage SCLC: a case report and mini literature review.
Mao Y; Huang M; Liu J
Lung Cancer Manag; 2024; 13(1):LMT64. PubMed ID: 38818367
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
[TBL] [Abstract][Full Text] [Related]
3. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
5. Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients.
Huang LL; Hu XS; Wang Y; Li JL; Wang HY; Liu P; Xu JP; He XH; Hao XZ; Jiang PD; Liu YT; Luo J; Zhou SY; Wang JW; Yang JL; Qin Y; Yuan P; Lin L; Shi YK
Thorac Cancer; 2021 Jul; 12(13):1943-1951. PubMed ID: 33969619
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab: A Review in Extensive-Stage SCLC.
Al-Salama ZT
Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
[TBL] [Abstract][Full Text] [Related]
7. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy.
Tian Y; Ma J; Jing X; Zhai X; Li Y; Guo Z; Yu J; Zhu H
Cancer Lett; 2022 Aug; 541():215719. PubMed ID: 35597478
[TBL] [Abstract][Full Text] [Related]
8. Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study.
Dawe DE; Rittberg R; Syed I; Shanahan MK; Moldaver D; Bucher O; Galloway K; Reynolds K; Paul JT; Harlos C; Kim JO; Banerji S
Front Oncol; 2023; 13():1191855. PubMed ID: 37795434
[TBL] [Abstract][Full Text] [Related]
9. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
[TBL] [Abstract][Full Text] [Related]
10. Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer.
Liu X; Xing H; Liu B
Am J Cancer Res; 2022; 12(6):2447-2464. PubMed ID: 35812062
[TBL] [Abstract][Full Text] [Related]
11. Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.
Lorenzi M; Resi MV; Bonanno L; Frega S; Dal Maso A; Ferro A; Guarneri V; Pasello G
Front Immunol; 2024; 15():1308109. PubMed ID: 38348046
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.
Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Harada T; Tamiya N; Chihara Y; Hiranuma O; Yamada T; Kanda H; Nakano T; Morimoto Y; Iwasaku M; Tokuda S; Takayama K
JTO Clin Res Rep; 2022 Jul; 3(7):100353. PubMed ID: 35789793
[TBL] [Abstract][Full Text] [Related]
13. The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer.
Lee YS; Lim JH; Ryu W; Park MH; Kim L; Kim K; Kim WY; Nam HS
Transl Lung Cancer Res; 2021 Jun; 10(6):2539-2550. PubMed ID: 34295660
[TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers for immunotherapy response in extensive-stage SCLC.
Zhu L; Qin J
J Cancer Res Clin Oncol; 2024 Jan; 150(1):22. PubMed ID: 38245636
[TBL] [Abstract][Full Text] [Related]
15. Serplulimab monotherapy in extensive-stage small-cell lung cancer with brain metastasis: a case report.
Xiang X; Li H; Lei B; Chen B; Li G
Immunotherapy; 2024 Mar; ():. PubMed ID: 38532729
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Nomogram for Overall Survival in Small Cell Lung Cancer Patients Treated with Chemotherapy: A SEER-Based Retrospective Cohort Study.
Liang M; Chen M; Singh S; Singh S
Adv Ther; 2022 Jan; 39(1):346-359. PubMed ID: 34729705
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy.
Valette CA; Filleron T; Debieuvre D; Lena H; Pérol M; Chouaid C; Simon G; Quantin X; Girard N
Respir Med Res; 2023 Nov; 84():101012. PubMed ID: 37307617
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
19. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Xue L; Chen B; Lin J; Peng J
Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
